129 related articles for article (PubMed ID: 7682753)
1. Fibrinolytic components in fetal membranes and amniotic fluid.
Watanabe T; Araki M; Mimuro J; Tamada T; Sakata Y
Am J Obstet Gynecol; 1993 Apr; 168(4):1283-9. PubMed ID: 7682753
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of plasminogen activators and plasminogen activator inhibitors in plasma and amniotic fluid in pregnancies complicated with intrauterine fetal growth retardation.
Gilabert J; Estellés A; Ayuso MJ; España F; Chirivella M; Grancha S; Micó JM; Aznar J
Gynecol Obstet Invest; 1994; 38(3):157-62. PubMed ID: 8001867
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen activator inhibitors type 1 and type 2 and plasminogen activators in amniotic fluid during pregnancy.
Estellés A; Gilabert J; Andrés C; España F; Aznar J
Thromb Haemost; 1990 Oct; 64(2):281-5. PubMed ID: 2125378
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activator activity and urokinase inhibitor activity in human amniotic fluid and fetal membranes.
Milwidsky A; Finci Z; Mayer M
Clin Biochem; 1988 Oct; 21(5):301-6. PubMed ID: 3233741
[TBL] [Abstract][Full Text] [Related]
5. Influence of delivery on plasminogen activator inhibitor activity.
Koelbl H; Kirchheimer J; Tatra G
J Perinat Med; 1989; 17(2):107-11. PubMed ID: 2681664
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen, alpha(2)-antiplasmin and complexes of plasmin-alpha(2)-antiplasmin (PAP) in amniotic fluid and blood plasma of parturient women.
Uszynski M; Klyszejko A; Zekanowska E
Eur J Obstet Gynecol Reprod Biol; 2000 Dec; 93(2):167-71. PubMed ID: 11074138
[TBL] [Abstract][Full Text] [Related]
7. Fibrinolytic activity in amniotic fluid during late pregnancy.
Pschera H; Kjaeldgaard A; Larsson B
Acta Obstet Gynecol Scand; 1986; 65(5):417-20. PubMed ID: 3776484
[TBL] [Abstract][Full Text] [Related]
8. Fluid characteristics of benign ovarian cysts: correlation with recurrence after puncture.
Andolf E; Casslén B; Jörgensen C; Buchhave P; Lecander I
Obstet Gynecol; 1995 Oct; 86(4 Pt 1):529-35. PubMed ID: 7675374
[TBL] [Abstract][Full Text] [Related]
9. Coagulation and fibrinolysis in amniotic fluid: physiology and observations on amniotic fluid embolism, preterm fetal membrane rupture, and pre-eclampsia.
Uszyński M; Uszyński W
Semin Thromb Hemost; 2011 Mar; 37(2):165-74. PubMed ID: 21370219
[TBL] [Abstract][Full Text] [Related]
10. The human fetal membranes: a target tissue for relaxin.
Koay ES; Bryant-Greenwood GD; Yamamoto SY; Greenwood FC
J Clin Endocrinol Metab; 1986 Mar; 62(3):513-21. PubMed ID: 3003143
[TBL] [Abstract][Full Text] [Related]
11. Fibrinolytic balance and lupus anticoagulant in patients with repeated spontaneous fetal loss.
Ferro D; Violi F; Quintarelli C; Sebastianelli A; D'Amelio R; Zichella L; Balsano F
BMJ; 1992 Aug; 305(6852):504-5. PubMed ID: 1392996
[No Abstract] [Full Text] [Related]
12. [Determination of the enzyme activity of the fibrinolytic system using fibrinogen conjugated with peroxidase].
Liaginskiĭ AV; AfanasenkoGA ; Gudkova EV
Lab Delo; 1991; (11):27-31. PubMed ID: 1722843
[TBL] [Abstract][Full Text] [Related]
13. Isolation of a new specific plasminogen activator inhibitor from pregnancy plasma.
Lecander I; Astedt B
Br J Haematol; 1986 Feb; 62(2):221-8. PubMed ID: 3484964
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activators in synovial fluid and plasma from patients with arthritis.
Brommer EJ; Dooijewaard G; Dijkmans BA; Breedveld FC
Ann Rheum Dis; 1992 Aug; 51(8):965-8. PubMed ID: 1417121
[TBL] [Abstract][Full Text] [Related]
15. [Intrauterine defensive mechanism of amniotic fluid and fetal membranes].
Kanayama N
Nihon Sanka Fujinka Gakkai Zasshi; 1994 Aug; 46(8):673-85. PubMed ID: 8089604
[TBL] [Abstract][Full Text] [Related]
16. Expression of tissue type and urokinase type plasminogen activators as well as plasminogen activator inhibitor type-1 and type-2 in human and rhesus monkey placenta.
Hu ZY; Liu YX; Liu K; Byrne S; Ny T; Feng Q; Ockleford CD
J Anat; 1999 Feb; 194 ( Pt 2)(Pt 2):183-95. PubMed ID: 10337950
[TBL] [Abstract][Full Text] [Related]
17. Abnormal expression of plasminogen activator inhibitors in patients with gestational trophoblastic disease.
Estellés A; Grancha S; Gilabert J; Thinnes T; Chirivella M; España F; Aznar J; Loskutoff DJ
Am J Pathol; 1996 Oct; 149(4):1229-39. PubMed ID: 8863672
[TBL] [Abstract][Full Text] [Related]
18. Urokinase plasminogen activator (uPA) and its receptor (uPAR) in gestational tissues; Measurements and clinical implications.
Uszyński M; Perlik M; Uszyński W; Zekanowska E
Eur J Obstet Gynecol Reprod Biol; 2004 May; 114(1):54-8. PubMed ID: 15099871
[TBL] [Abstract][Full Text] [Related]
19. Epithelial cell-derived neutrophil-activating peptide-78 is present in fetal membranes and amniotic fluid at increased concentrations with intra-amniotic infection and preterm delivery.
Keelan JA; Yang J; Romero RJ; Chaiworapongsa T; Marvin KW; Sato TA; Mitchell MD
Biol Reprod; 2004 Jan; 70(1):253-9. PubMed ID: 13679321
[TBL] [Abstract][Full Text] [Related]
20. Expression pattern of the plasminogen activator-plasmin system in human cholesteatoma.
Schönermark MP; Issing PR; Erbrich BK; Lenarz T
Ann Otol Rhinol Laryngol; 1999 Mar; 108(3):245-52. PubMed ID: 10086616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
